Check in: 2115
We arrive today at the end of our journey through the next 100 years. For the "Immortal Generation," this is a special year. For they are celebrating their 100th birthday. However, for most in this generation, this is far from the end. On the contrary, life expectancy forecasts have really skyrocketed in recent decades. New technologies in medicine and genetics have led to a "genome-based lifestyle" that has put Valentin and his peers on a different life path than his parents' generation. The new knowledge at the smallest, atomic level of how the human body works has made the "most important object on earth" designable. The consequence: less fate, more personal responsibility. But at the same time, this leads to completely new questions: Does infinite life make sense? Will there be arguments between gene-optimized and non-optimized children in our families? How does one decide when almost anything goes? And when do you die if you can live forever? Check in and join Valentin in his life in the year 2115.
If you want to get to know more about the future of genetics, watch the recording of the session here.
"Mr. Future" Sven Gábor Jánszky (48) is Germany's most sought-after futurologist. He is Chairman of the largest scientific futurology institute in Europe. With his clear, friendly manner, he translates the scientific methods of futurology and makes them understandable and applicable to everyone. Without chakka and esotericism, he helps people and companies to recognize their future environment, to develop their desirable future image and to achieve their best possible future self. He is the most booked speaker at future events and strategy conferences in the German economy. Hundreds of companies and board members work with his future studies and forecasts. His strategy recommendations shape the future strategies in corporations and medium-sized businesses. As a future coach, he has guided many thousands of participants in his seminars, influenced readers of his books, and educated the many subscribers to his online courses to their best possible personal future self.
The futurologist has taught at various universities in Leipzig, Greifswald, Göttingen and Karlsruhe. His trend books "2030 - How much people can the future take?", "2025 - This is how we will work in the future" and "2020 - This is how we will live in the future" shape the future strategies of various industries. With his management strategy books "Rulebreaker - How people think whose ideas change the world" (2010) and "Die Neuvermessung der Werte" (2014), he became a mouthpiece for disruptive innovators in German business. His book "The Recruiting Dilemma" explains the rapid change of the labor market towards full employment, the decline of long-term permanent employment, and the dissolution of HR departments.
He is Chairman of the 2b AHEAD ThinkTank in Germany, President of the international "RULEBREAKER Society" and founder and Managing Director of the two investment companies "2b AHEAD Ventures" and "RULEBREAKER Management". As a consultant, Janszky coaches executive boards and entrepreneurs in strategy processes, leads innovation processes to product development and business models of the future. Jánszky is a sought-after interview expert in Germany's media and keynote speaker at strategy conferences and congresses. Sven Gábor Jánszky lives with his wife and three children in a small village between Berlin and Leipzig. He was vice youth team GDR champion in chess in 1988. He climbed Kilimanjaro four times and ran his 19th marathon in New York.
Dr. Hou Yong was trained as a PhD in Bioinformatics at the University of Copenhagen and now works as a Research Scientist and Executive Director of BGI-Research. He is also a research associate at the University of Chinese Academy of Sciences. With a strong background in next-generation sequencing and data analysis and interpretation, especially in single-cell analysis and cancer research, he published more than 30 peer-reviewed scientific papers on journals such as Cell, Nature Biotechnology, Nature Communications, and Nature Communications, and was listed as a co-inventor of more than 30 patents in the field of genomics. He has provided more than RMB 20 million from national or local funders to investigate the clinical application of next-generation sequencing in cancer diagnosis. He is invited as a guest editor for Journal of Clinical and Translational Medicine on Clinical Bioinformatics Session and as a reviewer of Scientific Reports, BMC Bioinformatics, Oncotarget and Cell Biology and Toxicology. He is now focusing on translational research on the application of next generation sequencing and single cell analysis in cancer precision medicine.